A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

Guide for the Care and Use of Laboratory Animals: Eighth Edition

(2011) · doi:10.17226/12910 · Cited by 16,199 · see citing works

Direct Gene Transfer into Mouse Muscle in Vivo

Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · see citing works

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · see citing works

Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein

Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318 · see citing works

Modified mRNA vaccines protect against zika virus infection

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909 · see citing works

A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates

Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820 · see citing works

Enhanced antibody half-life improves in vivo activity

Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 657 · see citing works

A Mouse Model for Chikungunya: Young Age and Inefficient Type-I Interferon Signaling Are Risk Factors for Severe Disease

Couderc, T., Chrétien, F. C., Schilte, C., Disson, O., Brigitte, M., Guivel‐Benhassine, F., Touret, Y., Barau, G., Cayet, N., Schuffenecker, I., et al. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.0040029 · Cited by 621 · see citing works

Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005–2006 outbreak on Réunion

Economopoulou, A., Dominguez, M., Helynck, B., et al. (2008) · Epidemiology and Infection · doi:10.1017/s0950268808001167 · Cited by 571 · see citing works

Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.

Tao, M., & Morrison, S. L. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.8.2595 · Cited by 531 · see citing works

Chikungunya Virus Arthritis in Adult Wild-Type Mice

Gardner, J., Anraku, I., Le, T. T., Larcher, T., Major, L. D., Roques, P., Schroder, W. A., Higgs, S., & Suhrbier, A. (2010) · Journal of Virology · doi:10.1128/jvi.02603-09 · Cited by 439 · see citing works

Arrival of Chikungunya Virus in the New World: Prospects for Spread and Impact on Public Health

Weaver, S. C. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002921 · Cited by 396 · see citing works

Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques

Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.006 · Cited by 395 · see citing works

Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences

Acqua, W. F. D., Woods, R. M., Ward, E. S., Palaszynski, S., Patel, N., Brewah, Y. A., Wu, H., Kiener, P. A., & Langermann, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5171 · Cited by 368 · see citing works

IgG Fc engineering to modulate antibody effector functions

Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356 · see citing works

Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge

Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352 · see citing works

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

Johnson, P. R., Schnepp, B. C., Zhang, J., Connell, M. J., Greene, S. M., Yuste, E., Desrosiers, R. C., & Clark, K. R. (2009) · Nature Medicine · doi:10.1038/nm.1967 · Cited by 310 · see citing works

Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus

Pal, P., Dowd, K. A., Brien, J. D., Edeling, M. A., Gorlatov, S. N., Johnson, S., Lee, I. T., Akahata, W., Nabel, G. J., van Duijl-Richter, M. K. S., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003312 · Cited by 295 · see citing works

A Mouse Model of Chikungunya Virus–Induced Musculoskeletal Inflammatory Disease

Morrison, T. E., Oko, L. M., Montgomery, S. A., Whitmore, A. C., Lotstein, A. R., Gunn, B. M., Elmore, S. A., & Heise, M. T. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.018 · Cited by 290 · see citing works

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease

Richner, J. M., Jagger, B. W., Shan, C., Fontes, C. R., Dowd, K. A., Cao, B., Himansu, S., Caine, E. A., Nunes, B. T. D., Medeiros, D. B. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.040 · Cited by 267 · see citing works

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia

An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263 · see citing works

Development of an attenuated strain of chikungunya virus for use in vaccine production

Levitt, N. H., Ramsburg, H. H., Hasty, S. E., Repik, P. M., Cole, F. E., & Lupton, H. W. (1986) · Vaccine · doi:10.1016/0264-410x(86)90003-4 · Cited by 257 · see citing works

Epidemiology of Chikungunya in the Americas

Yactayo, S., Staples, J. E., Millot, V., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw390 · Cited by 254 · see citing works

Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission

Balazs, A. B., Ouyang, Y., Hong, C. M., Chen, J., Nguyen, S. M., Rao, D. S., An, D. S., & Baltimore, D. (2014) · Nature Medicine · doi:10.1038/nm.3471 · Cited by 237 · see citing works

Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress

Fox, J. M., Long, F., Edeling, M. A., Lin, H., van Duijl-Richter, M. K. S., Fong, R. H., Kahle, K. M., Smit, J. M., Jin, J., Simmons, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.050 · Cited by 223 · see citing works

Modified mRNA Vaccines Protect against Zika Virus Infection

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.016 · Cited by 221 · see citing works

Long-term sequelae of chikungunya virus disease: A systematic review

van Aalst, M., Nelen, C. M., Goorhuis, A., et al. (2017) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2017.01.004 · Cited by 207 · see citing works

Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus

Smith, S. A., Silva, L. A., Fox, J. M., Flyak, A. I., Kose, N., Sapparapu, G., Khomandiak, S., Ashbrook, A. W., Kahle, K. M., Fong, R. H., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.06.009 · Cited by 142 · see citing works

Induction of robust B cell responses after influenza mRNA vaccination Is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells

Lindgren, G., Ols, S., Liang, F., Thompson, E. A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K. J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01539 · Cited by 132 · see citing works

Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies.

Chappel, M. S., Isenman, D. E., Everett, M., Xu, Y. Y., Dorrington, K. J., & Klein, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.9036 · Cited by 131 · see citing works

Monoclonal Antibodies for Emerging Infectious Diseases — Borrowing from History

Marston, H. D., Paules, C. I., & Fauci, A. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1802256 · Cited by 125 · see citing works

Therapeutic antibodies for infectious diseases

Sparrow, E. G., Friede, M., Sheikh, M., & Torvaldsen, S. (2017) · Bulletin of the World Health Organization · doi:10.2471/blt.16.178061 · Cited by 120 · see citing works

Chikungunya virus: an update on antiviral development and challenges

Kaur, P., & Chu, J. J. H. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.002 · Cited by 107 · see citing works

Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis

Miner, J. J., Cook, L. E., Hong, J. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3438 · Cited by 103 · see citing works

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

Muthumani, K., Block, P. D., Flingai, S., Muruganandam, N., Chaaithanya, I. K., Tingey, C., Wise, M. C., Reuschel, E. L., Chung, C. W., Muthumani, A., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw111 · Cited by 91 · see citing works

Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling

Partidos, C. D., Weger‐Lucarelli, J., Brewoo, J. N., Seymour, R. L., Borland, E. M., Ledermann, J. P., Powers, A. M., Weaver, S. C., Stinchcomb, D. T., & Osorio, J. E. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.076 · Cited by 82 · see citing works

Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence

Hawman, D. W., Fox, J. M., Ashbrook, A. W., May, N. A., Schroeder, K., Torres, R. M., Crowe, J. E., Dermody, T. S., Diamond, M. S., & Morrison, T. E. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.076 · Cited by 80 · see citing works

Atypical Chikungunya Virus Infections in Immunocompromised Patients

Kee, A. C.-L., Yang, S. P., & Tambyah, P. A. (2010) · Emerging infectious diseases · doi:10.3201/eid1606.091115 · Cited by 75 · see citing works

Chimeric Chikungunya Viruses Are Nonpathogenic in Highly Sensitive Mouse Models but Efficiently Induce a Protective Immune Response

Wang, E., Kim, D., Weaver, S. C., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00844-11 · Cited by 75 · see citing works

Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques

Broeckel, R. M., Fox, J. M., Haese, N. N., et al. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0005637 · Cited by 70 · see citing works

Reovirus Cell Entry Requires Functional Microtubules

Mainou, B. A., Zamora, P. F., Ashbrook, A. W., Dorset, D. C., Kim, K. S., & Dermody, T. S. (2013) · mBio · doi:10.1128/mbio.00405-13 · Cited by 63 · see citing works

Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo

Duperret, E. K., Trautz, A., Stoltz, R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1429 · Cited by 51 · see citing works

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model

Patel, A. R., Park, D. H., Davis, C. W., Smith, T. R. F., Leung, A., Tierney, K. J., Bryan, A. L., Davidson, E., Yu, X., Racine, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.062 · Cited by 49 · see citing works

DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

Elliott, S. T. C., Kallewaard, N. L., Benjamin, E., Wachter-Rosati, L., McAuliffe, J. M., Patel, A. R., Smith, T. R. F., Schultheis, K., Park, D. H., Flingai, S., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0020-x · Cited by 48 · see citing works

A Game of Numbers

Pierson, T. C., & Diamond, M. (2014) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2014.10.005 · Cited by 46 · see citing works

Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab

Muthumani, K., Flingai, S., Wise, M. C., Tingey, C., Ugen, K. E., & Weiner, D. B. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26498 · Cited by 45 · see citing works

Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody

Muthumani, K., Marnin, L., Kudchodkar, S. B., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2042-7 · Cited by 41 · see citing works

Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics

Khoshnejad, M., Patel, A. R., Wojtak, K., Kudchodkar, S. B., Humeau, L. M. P. F., Lyssenko, N. N., Rader, D. J., Muthumani, K., & Weiner, D. B. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.016 · Cited by 39 · see citing works

Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters

Brandenberg, O. F., Magnus, C., Rusert, P., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006313 · Cited by 29 · see citing works

An overview on safety of monoclonal antibodies

Matucci, A., Nencini, F., Pratesi, S., et al. (2016) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000315 · Cited by 24 · see citing works

Chikungunya and Neonatal Immunity: Fatal Vertically Transmitted Chikungunya Infection

Evans-Gilbert, T. (2017) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.16-0491 · Cited by 24 · see citing works

Safety of Therapeutic Monoclonal Antibodies

Niebecker, R., & Kloft, C. (2010) · Current Drug Safety · doi:10.2174/157488610792246055 · Cited by 23 · see citing works

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works

The evolution of commercial drug delivery technologies

Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361 · see citing works

Nanomaterial Delivery Systems for mRNA Vaccines

Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021) · Vaccines · doi:10.3390/vaccines9010065 · Cited by 582 · see citing works

The promise of mRNA vaccines: a biotech and industrial perspective

Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498 · see citing works

Lipid nanoparticle technology for therapeutic gene regulation in the liver

Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.026 · Cited by 376 · see citing works

An Update on Self-Amplifying mRNA Vaccine Development

Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288 · see citing works

Eliciting B cell immunity against infectious diseases using nanovaccines

Singh, A. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00790-3 · Cited by 169 · see citing works

Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans

Cagigi, A., & Loré, K. (2021) · Vaccines · doi:10.3390/vaccines9010061 · Cited by 153 · see citing works

Mild Innate Immune Activation Overrides Efficient Nanoparticle‐Mediated RNA Delivery

Lokugamage, M. P., Gan, Z., Zurla, C., Levin, J., Islam, F. Z., Kalathoor, S., Sato, M., Sago, C. D., Santangelo, P. J., & Dahlman, J. E. (2020) · Advanced Materials · doi:10.1002/adma.201904905 · Cited by 126 · see citing works

Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection

Erasmus, J. H., Archer, J., Fuerte-Stone, J., Khandhar, A. P., Voigt, E., Granger, B., Bombardi, R. G., Govero, J., Tan, Q., Durnell, L. A., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.011 · Cited by 118 · see citing works

Non-immunotherapy application of LNP-mRNA: Maximizing efficacy and safety

Vlatkovic, I. (2021) · Biomedicines · doi:10.3390/biomedicines9050530 · Cited by 112 · see citing works

mRNA Vaccines against Flaviviruses

Wollner, C. J., & Richner, J. M. (2021) · Vaccines · doi:10.3390/vaccines9020148 · Cited by 44 · see citing works

From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases

Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23 · see citing works

[The chikungunya epidemic in the Caribbean: implications for travellers and physicians].

Cleton, N. B., Reusken, C. B. E. M., & Gorp, E. C. M. V. (2014) · PubMed · Cited by 2 · see citing works

Intermittent low-level viremia in very early primary HIV-1 infection.

Fiebig, E. W., Heldebrant, C. M., Smith, R. I. F., Conrad, A. J., Delwart, E., & Busch, M. P. (2005) · PubMed · Cited by 48 · see citing works

Extensive characterization of HIV-1 reservoirs reveals links to plasma viremia before and during analytical treatment interruption

Cole, B., Lambrechts, L., Boyer, Z., Noppe, Y., Scheerder, M. D., Eden, J., Vrancken, B., Schlub, T. E., McLaughlin, S., Frenkel, L. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110739 · Cited by 35 · see citing works

A Mouse Model for Studying Post-Acute Arthritis of Chikungunya

Chang, A. Y., Tritsch, S. R., Porzucek, A. J., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9091998 · Cited by 13 · see citing works

Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia

Medina-Ramírez, M., Sánchez-Merino, V., Sánchez‐Palomino, S., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02482-10 · Cited by 46 · see citing works